CAC
BPMC

Cowen and Company’s Blueprint Medicines BPMC Stock Holding History

Cowen and Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-38,353
Closed -$3.54M – 681
2023
Q4 		$3.54M Buy
+38,353
New +$2.49M 0.23% 74
2020
Q2 		– Sell
-4,999
Closed -$338K – 405
2020
Q1 		$292K Buy
+4,999
New +$322K 0.07% 165

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen and Company's BPMC Position: Q1 2024 in Review

Cowen and Company sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 38,353 shares — an estimated $3.54M sold.

Cowen and Company first reported a position in BPMC in Q1 2020 and held it in 2 quarters. The position peaked at $3.54M in Q4 2023. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • Cowen and Company reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 38,353 Blueprint Medicines shares in Q1 2024, an estimated $3.54M.
  • Cowen and Company first reported a position in Blueprint Medicines in Q1 2020 and held it in 2 quarters.
  • Cowen and Company's Blueprint Medicines position peaked at $3.54M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.